Article tools
Author information
Published in Volume 61, Issue 4 (April , 1978)
J. Clin. Invest. 61(4): 973-980 (1978). doi:10.1172/JCI109022.
Copyright © 1978, The American Society for Clinical Investigation

Articles

Loss of Central Nervous System Component of Dopaminergic Inhibition of Prolactin Secretion in Patients with Prolactin-Secreting Pituitary Tumors

Stuart A. Fine and Lawrence A. Frohman

Division of Endocrinology and Metabolism, Department of Medicine, Michael Reese Hospital and University of Chicago, Chicago, Illinois 60616 Pritzker School of Medicine, Chicago, Illinois 60616

Published April , 1978

The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. To distinguish between these effects, 10 normal subjects (6 male, 4 female) and 8 patients with hyperprolactinemia associated with pituitary tumors were given l-dopa, 0.5 g alone, or 0.1 g after a 24-h pretreatment with carbidopa, 50 mg every 6 h, which produces peripheral dopa decarboxylase inhibition. Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13±2 ng/ml) after l-dopa alone (48±4%) and after l-dopa plus carbidopa (58±6%). In patients with pituitary tumors and elevated plasma PRL (73±14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47±6%). However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19±4%) which was significantly less than after l-dopa alone (P < 0.001). Urinary homovanillic acid excretion, which reflected peripheral dopa decarboxylation was similar in controls and tumor patients after l-dopa both alone and after carbidopa pretreatment. Comparable suppression of PRL levels in response to a dopamine infusion (4 μg/kg per min for 3 h) was observed in controls and tumor patients. The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. In contrast, patients with tumors, while retaining peripheral dopaminergic inhibitory effects on PRL secretion, exhibit a marked reduction of central dopaminergic inhibition of PRL secretion.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 973
icon of scanned page 974
icon of scanned page 975
icon of scanned page 976
icon of scanned page 977
icon of scanned page 978
icon of scanned page 979
icon of scanned page 980

This article Copyright © 1978, The American Society for Clinical Investigation.

Articles that cite this article:

FOLLOW-UP OF PROLACTIN LEVELS IN LONG-TERM OESTROGEN-TREATED MALE-TO-FEMALE TRANSSEXUALS WITH REGARD TO PROLACTINOMA INDUCTION
L. J. G. Gooren, W. Harmsen-louman, H. Kessel
Clin Endocrinol (Oxf) 22(2):201. doi:10.1111/j.1365-2265.1985.tb01081.x [CrossRef]

RECIPROCAL PATTERN OF THE TSH AND PRL RESPONSES TO DOPAMINE RECEPTOR BLOCKADE IN WOMEN WITH PHYSIOLOGICAL OR PATHOLOGICAL HYPERPROLACTINAEMIA
F. Massara, F. Camanni, M. Martra, G. C. Dolfin, E. E. MÜller, G. M. Molinatti
Clin Endocrinol (Oxf) 18(2):103. doi:10.1111/j.1365-2265.1983.tb03191.x [CrossRef]

THE INTERRELATIONSHIPS BETWEEN PROLACTIN AND THYROTROPHIN SECRETION FOLLOWING DOPAMINERGIC BLOCKAGE IN PATIENTS WITH MILD HYPERPROLACTINAEMIA WITHOUT ANY DEMONSTRABLE PITUITARY TUMOUR
J. M. Spitz, M. Haas, S. Trestian, E. Zylber-haran, S. Shilo
Clin Endocrinol (Oxf) 19(3):285. doi:10.1111/j.1365-2265.1983.tb00001.x [CrossRef]

PROLACTIN STIMULATION BY INTRAVENOUS LABETALOL IS MEDIATED INSIDE THE CENTRAL NERVOUS SYSTEM
CRISTIANO Barbieri, MARIA TERESA Larovere, GIANCARLO Mariotti, CARLO Ferrari, ROBERTO Caldara
Clin Endocrinol (Oxf) 16(6):615. doi:10.1111/j.1365-2265.1982.tb03178.x [CrossRef]

THE PREOPERATIVE AND POSTOPERATIVE INVESTIGATION OF TSH AND PROLACTIN RELEASE IN THE MANAGEMENT OF PATIENTS WITH HYPERPROLACTINAEMIA DUE TO PROLACTINOMAS AND NONFUNCTIONAL PITUITARY TUMOURS: RELATIONSHIP TO ADENOMA SIZE AT SURGERY
M. F. Scanlon, J. R. Peters, J. Salvador, S. H. Richards, R. John, S. Howell, E. D. Williams, J. P. Thomas, R. Hall
Clin Endocrinol (Oxf) 24(4):435. doi:10.1111/j.1365-2265.1986.tb01649.x [CrossRef]

EFFECT OF DOPAMINE INFUSION ON SERUM PROLACTIN CONCENTRATION IN NORMAL AND HYPERPROLACTINAEMIC SUBJECTS
E. Reschini, C. Ferrari, M. Peracchi, R. Fadini, M. Meschia, P. G. Crosignani
Clin Endocrinol (Oxf) 13(6):519. doi:10.1111/j.1365-2265.1980.tb03419.x [CrossRef]

LONG-TERM FOLLOW-UP OF‘CURED’PROLACTINOMA PATIENTS AFTER SUCCESSFUL ADENOMECTOMY
ENRICA Ciccarelli, EZIO Ghigo, CATALDO Miola, GIOVANNI Gandini, EUGENIO E. Muller, FRANCO Camanni
Clin Endocrinol (Oxf) 32(5):583. doi:10.1111/j.1365-2265.1990.tb00901.x [CrossRef]

Dopamine, the dopamine D2 receptor and pituitary tumours
D. F. Wood, J. M. Johnston, D. G. Johnston
Clin Endocrinol (Oxf) 35(6):455. doi:10.1111/j.1365-2265.1991.tb00928.x [CrossRef]

PULSATILE GONADOTROPHIN SECRETION IN HYPERPROLACTINAEMIC AMENORRHOEA AND THE RESPONSE TO BROMOCRIPTINE THERAPY
P. J. A. Moult, LESLEY H. Rees, G. M. Besser
Clin Endocrinol (Oxf) 16(2):153. doi:10.1111/j.1365-2265.1982.tb03159.x [CrossRef]

ALTERED DOPAMINERGIC REGULATION OF THYROTROPHIN RELEASE IN PATIENTS WITH PROLACTINOMAS: COMPARISON WITH OTHER TESTS OF HYPOTHALAMIC-PITUITARY FUNCTION
M. F. Scanlon, M. D. Rodriguez-arnao, A. M. Mcgregor, D. Weightman, M. Lewis, D. B. Cook, A. Gomez-pan, R. Hall
Clin Endocrinol (Oxf) 14(2):133. doi:10.1111/j.1365-2265.1981.tb00608.x [CrossRef]

Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia
Fernando Larrea, José Luis Sandoval, Elizabeth Salinas, Ventura A. Franco-rodriguez, Isabel Méndez, Alfredo Ulloa-aguirre
Clin Endocrinol (Oxf) 43(5):591. doi:10.1111/j.1365-2265.1995.tb02924.x [CrossRef]

LONG-TERM BROMOCRIPTINE THERAPY MAY RESTORE THE INHIBITORY CONTROL OF PROLACTIN RELEASE IN SOME PATIENTS WITH PATHOLOGICAL HYPERPROLACTINEMIA
K. Y. Ho, G. A. Smythe, P. J. Compton, L. Lazarus
Intern Med J 15(2):213. doi:10.1111/j.1445-5994.1985.tb04009.x [CrossRef]

Tamoxifen Inhibits GH3 Cell Growth in Culture via Enhancement of Apoptosis
So-Young Lee, Byung Tae Ahn, Sang-Ho Baik, Byung-Lan Lee
Neurosurg 43(1):116. doi:10.1097/00006123-199807000-00076 [CrossRef]

Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia
R. Gerli, C. Riccardi, I. Nicoletti, S. Orlandi, C. Cernetti, F. Spinozzi, P. Rambotti
J Clin Immunol 7(6):463. doi:10.1007/BF00915056 [CrossRef]